Additional offer of sigmoidoscopy in colorectal cancer screening in Germany: rationale and protocol of the decision-analytic modelling approach in the SIGMO study.
endoscopy
gastrointestinal tumours
health economics
preventive medicine
public health
statistics & research methods
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
06 Jan 2022
06 Jan 2022
Historique:
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
16
3
2022
Statut:
epublish
Résumé
In Germany, statutory insured persons are entitled to a stool test (faecal immunochemical test (FIT)) or colonoscopy for colorectal cancer (CRC) screening, depending on age and sex, yet participation rates are rather low. Sigmoidoscopy is a currently not available screening measure that has a strong evidence base for incidence and mortality reduction. Due to its distinct characteristics, it might be preferred by some, who now reject colonoscopy. The objective of this study is to estimate the economic consequences of the additional offer of sigmoidoscopy for CRC screening in Germany compared with the present screening practice while considering the preferences of the general population. A decision-analytic modelling approach will be developed that compares the present CRC screening programme in Germany (FIT, colonoscopy) with a programme extended by sigmoidoscopy from a societal perspective. A decision tree and Markov model will be combined to assess both short-term and long-term effects, such as CRC and adenoma detection rates, the number of CRC cases, CRC mortality as well as complications. The incremental cost per quality-adjusted life year gained for each alternative will be calculated. The model will incorporate the general population's preferences based on a discrete choice experiment. Further, input parameters will be taken from the literature, the German cancer registry and health insurance claims data. Ethical approval for the study was obtained from the Ethics Committee of Hannover Medical School (ID: 8671_BO_K_2019). The findings of the study will be published in peer-reviewed journals and presented at national and/or international conferences. DRKS00019010.
Identifiants
pubmed: 34992106
pii: bmjopen-2021-050698
doi: 10.1136/bmjopen-2021-050698
pmc: PMC8739067
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e050698Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Br J Cancer. 2012 May 22;106(11):1875-80
pubmed: 22555397
Patient. 2014;7(3):271-82
pubmed: 24652475
JAMA. 2016 Jun 21;315(23):2576-94
pubmed: 27305422
BMJ Open. 2021 Jan 21;11(1):e042399
pubmed: 33478964
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216
pubmed: 17253456
Appl Health Econ Health Policy. 2016 Jun;14(3):253-66
pubmed: 26992386
J Med Screen. 2011;18(3):128-34
pubmed: 22045821
Med Decis Making. 2012 Sep-Oct;32(5):667-77
pubmed: 22990082
Med Decis Making. 1997 Jul-Sep;17(3):241-62
pubmed: 9219185
Endoscopy. 2012 Sep;44 Suppl 3:SE164-85
pubmed: 23012120
Clin Gastroenterol Hepatol. 2019 Sep;17(10):1969-1981.e15
pubmed: 30659991
Cancer Control. 2015 Apr;22(2):248-58
pubmed: 26068773
Patient Prefer Adherence. 2018 Oct 31;12:2267-2282
pubmed: 30464417
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1043-51
pubmed: 23632815
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Expert Rev Med Devices. 2013 Jul;10(4):489-99
pubmed: 23895076
Epidemiol Rev. 2011;33:88-100
pubmed: 21633092
Med Decis Making. 2012 Sep-Oct;32(5):690-700
pubmed: 22990084
World J Gastroenterol. 2017 May 28;23(20):3632-3642
pubmed: 28611516
Lancet. 2017 Apr 1;389(10076):1299-1311
pubmed: 28236467
BMJ. 2014 Apr 09;348:g2467
pubmed: 24922745
Cancer. 2010 Oct 15;116(20):4872-81
pubmed: 20597133
Endoscopy. 2013;45(2):142-50
pubmed: 23335011
BMJ Open. 2019 Oct 2;9(10):e032773
pubmed: 31578199